Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Former Names B6.Cg-Gusbmps/J    (Changed: 03-OCT-06 ) Type Congenic; Mutant Strain; Spontaneous Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Generation N10pN1 Generation Definitions   Donating Investigator Brian Soper,   The Jackson Laboratory

Description
Mice homozygous for the "mps" (mucopolysaccharidosis type VII or MPS VII) mutation are devoid of expression of the lysosomal enzyme beta glucuronidase. Homozygous animals are viable, but females have a deficiency in lactation. Skeletal and connective tissue anomalies in both males and females are believed to prevent successful breeding. As this mutation is recessive, heterozygous mice are phenotypically similar to wildtype. Homozygotes exhibit short and thickened long bones (smaller than heterozygous or wildtype littermates), "pug type" appearance of the nose, hepatomegaly, splenomegaly, corneal clouding, and deafness. These mice have the H2^b haplotype typical of inbred C57BL/6 mice. MPS VII mice are a model of the beta glucuronidase enzyme deficiency in humans called Sly Disease. They may be useful in developing new therapies (enzyme replacement, cell transplantation, gene therapy) broadly applicable to other lysosomal storage diseases.

Development
A spontaneous point mutation within exon 10 of the beta glucuronidase gene created a frameshift mutation that results in a premature stop codon. This mutation (called mucopolysaccharidosis type VII or MPS VII) arose in B6.C-H2^bm1/ByBir-Gusb^mps/J mice (Stock No. 000256). Mutants have been backcrossed with C57BL/6J (Stock No. 000664) mice for at least 10 generations by Dr. Jane Barker at The Jackson Laboratory.

Control Information

	Control
	Wild-type from the colony
	000664 C57BL/6J
Considerations for Choosing Controls

Related Strains

Strains carrying   Gusb^mps allele

006564	B6(C)-KitW-41J Gusbmps/BrkJ
006559	B6.C-H2-Kbm1/ByBir-Gusbmps/BrkJ
000256	B6.C-H2-Kbm1/ByBir-Gusbmps/J
006562	B6.CBy(Cg)-Gusbmps Gpi1a-m1J/BrkJ
002086	B6.Cg-Gusbmps Tg(Gussx)1Wat/J
005053	NOD.Cg-Prkdcscid Gusbmps/SndsJ
001880	STOCK Gusbmps Tg(GUSB)4Sly/BirJ

View Strains carrying   Gusb^mps     (7 strains)

Strains carrying other alleles of Gusb

005643	B6.129X-Gusbtm1Sly/J
005644	B6.129X-Gusbtm3Sly/J
001603	B6.A-Gusba/J
001598	B6.C3-Gusbh/J
006557	B6.C3-Gusbmps-2J/BrkJ
001599	B6.CAST-Gusbcs/J
001604	B6.Cg-Ces1cb Ces1eh Gusbh/J
001605	B6.Cg-Gusbw12/CvJ
001608	B6.Cg-Gusbw26/CvJ
001602	B6.MOR-Gusbw5/CvJ
001597	B6.PAC-Gusbn/J
003525	C3H/HeOuJ-Gusbmps-2J/BrkJ
005322	C57BL/6J-Gusbmps-3J/J

View Strains carrying other alleles of Gusb     (13 strains)

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms provided by MGI

- Model with phenotypic similarity to human disease where etiologies involve orthologs. Human genes are associated with this disease. Orthologs of those genes appear in the mouse genotype(s).

Mucopolysaccharidosis Type VII

View Mammalian Phenotype Terms

Mammalian Phenotype Terms provided by MGI

      assigned by genotype

Gusb^mps/Gusb^mps

        involves: C57BL/6By

• mortality/aging
• premature death
  • death between 150 and 200 days   (MGI Ref ID J:13923)
• adipose tissue phenotype
• decreased white adipose tissue amount
  • absent, but normal brown fat amount   (MGI Ref ID J:13923)
• craniofacial phenotype
• short snout   (MGI Ref ID J:13923)
• endocrine/exocrine gland phenotype
• abnormal lactation
  • inadequate lactation to nurture pups   (MGI Ref ID J:13923)
• growth/size phenotype
• decreased body length   (MGI Ref ID J:13923)
• disproportionate dwarf
  • subtle   (MGI Ref ID J:13923)
• homeostasis/metabolism phenotype
• decreased circulating cholesterol level
  • compared to littermate controls   (MGI Ref ID J:13923)
• increased urine glycosaminoglycan level
  • increase in urinary glycosaminoglycan levels   (MGI Ref ID J:87155)
• limbs/digits/tail phenotype
• short limbs   (MGI Ref ID J:13923)
• short tail   (MGI Ref ID J:13923)
• reproductive system phenotype
• male infertility
  • sterility not due to reproductive or gonadal tract dysmorphology or to sperm numbers, morphology, or motility   (MGI Ref ID J:13923)
• skeleton phenotype
• abnormal skeleton morphology
  • mutant bones shorter and thicker than littermate controls, but contain same amount of mineralization   (MGI Ref ID J:13923)
• renal/urinary system phenotype
• increased urine glycosaminoglycan level
  • increase in urinary glycosaminoglycan levels   (MGI Ref ID J:87155)
• integument phenotype
• abnormal lactation
  • inadequate lactation to nurture pups   (MGI Ref ID J:13923)

Gusb^mps/Gusb^mps

        B6.Cg-Gusb^mps/BrkJ

• cellular phenotype
• abnormal cell morphology
  • elevation of hexuronic acid levels in tissues indicating glycosaminoglycan storage   (MGI Ref ID J:21256)
• • abnormal lysosome morphology
    • lysosomal storage disease   (MGI Ref ID J:21256)
• homeostasis/metabolism phenotype
• abnormal enzyme/ coenzyme level
  • homozygotes exhibit an elevation of many lysosomal enzymes, including beta-hexosaminidase, beta-galactosidase, alpha-mannosidase, acid phosphatase, aryl sulfatase A, and alpha-fucosidase   (MGI Ref ID J:21256)
• renal/urinary system phenotype
• abnormal renal glomerulus morphology
  • visceral epithelial cells of the glomerulus are distended by enlarged lysosomes containing fine fibrillar material and small fragments of membranous debris   (MGI Ref ID J:21256)

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Developmental Biology Research
Skeletal Defects

Internal/Organ Research
Kidney Defects
      lysosomal enzyme abnormalities
Liver Defects
Spleen Defects

Mouse/Human Gene Homologs
deafness
mucopolysaccharidosis type VII, GUSB deficiency

Research Tools
Reproductive Biology Research

Sensorineural Research
Eye Defects

Gusb^mps related

Developmental Biology Research
Growth Defects
      Growth Defects (homozygous)
Skeletal Defects

Metabolism Research

Mouse/Human Gene Homologs
mucopolysaccharidosis type VII, GUSB deficiency

Neurobiology Research
Behavioral and Learning Defects

Sensorineural Research

Genes & Alleles

Gene & Allele Information provided by MGI

Allele Symbol		Gusbmps
Allele Name		beta glucuronidase, mucopolysaccharidosis VII
Allele Type		Spontaneous
Common Name(s)		Gus-b; MPS VII; asd; gusmps;
Mutation Made By		Brian Soper,   The Jackson Laboratory
Strain of Origin		B6.C-H2-Kbm1/By
Gene Symbol and Name		Gusb, glucuronidase, beta
Chromosome		5
Gene Common Name(s)		AI747421; Ac2-223; BG; Gur; Gus; Gus-r; Gus-s; Gus-t; Gus-u; Gut; MPS7; adipose storage deficiency; asd; beta-glucuronidase regulator; beta-glucuronidase structural; beta-glucuronidase systemic regulator; beta-glucuronidase temporal; expressed sequence AI747421; g;
Molecular Note		A 1-bp deletion creates a frameshift mutation within exon 10, which introduces a premature stop codon at codon 497. [MGI Ref ID J:13207]

Genotyping

Genotyping Information

Genotyping Protocols

Gusb^mps, Pyrosequencing
Gusb^mps, Restriction Enzyme Digest

Helpful Links

Genotyping resources and troubleshooting

References

References provided by MGI

Selected Reference(s)

Lessard MD; Alley TL; Proctor JL; Levy B; Galvin N; Vogler CA; Soper BW. 2006. Attenuation of murine lysosomal storage disease by allogeneic neonatal bone marrow transplantation using costimulatory blockade and donor lymphocyte infusion without myeloablation. Clin Immunol 119(2):166-79. [PubMed: 16487752]  [MGI Ref ID J:112478]

Schuldt AJ; Hampton TJ; Chu V; Vogler CA; Galvin N; Lessard MD; Barker JE. 2004. Electrocardiographic and other cardiac anomalies in beta-glucuronidase-null mice corrected by nonablative neonatal marrow transplantation. Proc Natl Acad Sci U S A 101(2):603-8. [PubMed: 14704281]  [MGI Ref ID J:112477]

Soper BW; Lessard MD; Jude CD; Schuldt AJ; Bunte RM; Barker JE. 2003. Successful allogeneic neonatal bone marrow transplantation devoid of myeloablation requires costimulatory blockade. J Immunol 171(6):3270-7. [PubMed: 12960357]  [MGI Ref ID J:112476]

Vogler C; Levy B; Galvin N; Lessard M; Soper B; Barker J. 2005. Early onset of lysosomal storage disease in a murine model of mucopolysaccharidosis type VII: undegraded substrate accumulates in many tissues in the fetus and very young MPS VII mouse. Pediatr Dev Pathol 8(4):453-62. [PubMed: 16222480]  [MGI Ref ID J:112479]

Additional References

Gusb^mps related

Alfaro MP; Pagni M; Vincent A; Atkinson J; Hill MF; Cates J; Davidson JM; Rottman J; Lee E; Young PP. 2008. The Wnt modulator sFRP2 enhances mesenchymal stem cell engraftment, granulation tissue formation and myocardial repair. Proc Natl Acad Sci U S A 105(47):18366-71. [PubMed: 19017790]  [MGI Ref ID J:142215]

Baldo G; Wu S; Howe RA; Ramamoothy M; Knutsen RH; Fang J; Mecham RP; Liu Y; Wu X; Atkinson JP; Ponder KP. 2011. Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab 104(4):608-19. [PubMed: 21944884]  [MGI Ref ID J:178881]

Barker JE; Deveau S; Lessard M; Hamblen N; Vogler C; Levy B. 2001. In Utero Fetal Liver Cell Transplantation without Toxic Irradiation Alleviates Lysosomal Storage in Mice with Mucopolysaccharidosis Type VII. Blood Cells Mol Dis 27(5):861-73. [PubMed: 11783949]  [MGI Ref ID J:72147]

Bastedo L; Sands MS; Lambert DT; Pisa MA; Birkenmeier E; Chang PL. 1994. Behavioral consequences of bone marrow transplantation in the treatment of murine mucopolysaccharidosis type VII. J Clin Invest 94(3):1180-6. [PubMed: 8083358]  [MGI Ref ID J:20455]

Beamer WG; Coleman DL. 1982. [Adipose storage deficiency (asd)]. Mouse News Lett 67:21.  [MGI Ref ID J:13923]

Berry CL; Vogler C; Galvin NJ; Birkenmeier EH; Sly WS. 1994. Pathology of the ear in murine mucopolysaccharidosis type VII. Morphologic correlates of hearing loss. Lab Invest 71(3):438-45. [PubMed: 7933993]  [MGI Ref ID J:20883]

Birkenmeier EH; Barker JE; Vogler CA; Kyle JW; Sly WS; Gwynn B; Levy B; Pegors C. 1991. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 78(11):3081-92. [PubMed: 1954394]  [MGI Ref ID J:1655]

Birkenmeier EH; Davisson MT; Beamer WG; Ganschow RE; Vogler CA; Gwynn B; Lyford KA; Maltais LM; Wawrzyniak CJ. 1989. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 83(4):1258-6. [PubMed: 2495302]  [MGI Ref ID J:9705]

Casal ML; Wolfe JH. 2000. Mucopolysaccharidosis type VII in the developing mouse fetus Pediatr Res 47(6):750-6. [PubMed: 10832732]  [MGI Ref ID J:63383]

Casal ML; Wolfe JH. 1998. Variant clinical course of mucopolysaccharidosis type VII in two groups of mice carrying the same mutation. Lab Invest 78(12):1575-81. [PubMed: 9881957]  [MGI Ref ID J:51808]

Chang PL; Lambert DT; Pisa MA. 1993. Behavioural abnormalities in a murine model of a human lysosomal storage disease. Neuroreport 4(5):507-10. [PubMed: 8513128]  [MGI Ref ID J:15184]

Chen YH; Chang M; Davidson BL. 2009. Molecular signatures of disease brain endothelia provide new sites for CNS-directed enzyme therapy. Nat Med 15(10):1215-8. [PubMed: 19749771]  [MGI Ref ID J:154308]

Daly TM; Vogler C; Levy B; Haskins ME; Sands MS. 1999. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci U S A 96(5):2296-300. [PubMed: 10051635]  [MGI Ref ID J:53359]

Donsante A; Vogler C; Muzyczka N; Crawford JM; Barker J; Flotte T; Campbell-Thompson M; Daly T; Sands MS. 2001. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 8(17):1343-6. [PubMed: 11571571]  [MGI Ref ID J:71706]

Faust JR; Rodman JS; Daniel PF; Dice JF; Bronson RT. 1994. Two related proteolipids and dolichol-linked oligosaccharides accumulate in motor neuron degeneration mice (mnd/mnd), a model for neuronal ceroid lipofuscinosis. J Biol Chem 269(13):10150-5. [PubMed: 8144516]  [MGI Ref ID J:17522]

Freeman BJ; Roberts MS; Vogler CA; Nicholes A; Hofling AA; Sands MS. 1999. Behavior and therapeutic efficacy of beta-glucuronidase-positive mononuclear phagocytes in a murine model of mucopolysaccharidosis type VII. Blood 94(6):2142-50. [PubMed: 10477745]  [MGI Ref ID J:57636]

Frischmeyer-Guerrerio PA; Montgomery RA; Warren DS; Cooke SK; Lutz J; Sonnenday CJ; Guerrerio AL; Dietz HC. 2011. Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc Natl Acad Sci U S A 108(26):10638-43. [PubMed: 21670277]  [MGI Ref ID J:173551]

Ghodsi A; Stein C; Derksen T; Martins I; Anderson RD; Davidson BL. 1999. Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp Neurol 160(1):109-16. [PubMed: 10630195]  [MGI Ref ID J:58538]

Hofling AA; Vogler C; Creer MH; Sands MS. 2003. Engraftment of human CD34+ cells leads to widespread distribution of donor-derived cells and correction of tissue pathology in a novel murine xenotransplantation model of lysosomal storage disease. Blood 101(5):2054-63. [PubMed: 12406886]  [MGI Ref ID J:109848]

Kyle JW; Birkenmeier EH; Gwynn B; Vogler C; Hoppe PC; Hoffmann JW; Sly WS. 1990. Correction of murine mucopolysaccharidosis VII by a human beta-glucuronidase transgene. Proc Natl Acad Sci U S A 87(10):3914-8. [PubMed: 2111021]  [MGI Ref ID J:21256]

Li B; Sharpe EE; Maupin AB; Teleron AA; Pyle AL; Carmeliet P; Young PP. 2006. VEGF and PlGF promote adult vasculogenesis by enhancing EPC recruitment and vessel formation at the site of tumor neovascularization. FASEB J 20(9):1495-7. [PubMed: 16754748]  [MGI Ref ID J:111344]

Meng XL; Shen JS; Kawagoe S; Ohashi T; Brady RO; Eto Y. 2010. Induced pluripotent stem cells derived from mouse models of lysosomal storage disorders. Proc Natl Acad Sci U S A 107(17):7886-91. [PubMed: 20385825]  [MGI Ref ID J:159373]

Metcalf JA; Zhang Y; Hilton MJ; Long F; Ponder KP. 2009. Mechanism of shortened bones in mucopolysaccharidosis VII. Mol Genet Metab 97(3):202-11. [PubMed: 19375967]  [MGI Ref ID J:150606]

Monroy MA; Ross FP; Teitelbaum SL; Sands MS. 2002. Abnormal osteoclast morphology and bone remodeling in a murine model of a lysosomal storage disease. Bone 30(2):352-9. [PubMed: 11856642]  [MGI Ref ID J:109426]

Moullier P; Bohl D; Heard JM; Danos O. 1993. Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts [see comments] Nat Genet 4(2):154-9. [PubMed: 8348154]  [MGI Ref ID J:11889]

Niermann GL; Watson GL. 1999. Growth hormone and insulin-like growth factor-I enhance beta-glucuronidase gene activation by androgen in mouse kidney. Mol Cell Endocrinol 153(1-2):47-55. [PubMed: 10459853]  [MGI Ref ID J:56310]

O'Connor LH; Erway LC; Vogler CA; Sly WS; Nicholes A; Grubb J; Holmberg SW; Levy B; Sands MS. 1998. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J Clin Invest 101(7):1394-400. [PubMed: 9525982]  [MGI Ref ID J:46825]

Ohashi T; Watabe K; Uehara K; Sly WS; Vogler C; Eto Y. 1997. Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A 94(4):1287-92. [PubMed: 9037045]  [MGI Ref ID J:38613]

Ohlemiller KK; Hennig AK; Lett JM; Heidbreder AF; Sands MS. 2002. Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 169(1-2):69-84. [PubMed: 12121741]  [MGI Ref ID J:108876]

Ohlemiller KK; Vogler CA; Roberts M; Galvin N; Sands MS. 2000. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation Exp Eye Res 71(5):469-81. [PubMed: 11040082]  [MGI Ref ID J:66030]

Parente MK; Rozen R; Cearley CN; Wolfe JH. 2012. Dysregulation of gene expression in a lysosomal storage disease varies between brain regions implicating unexpected mechanisms of neuropathology. PLoS One 7(3):e32419. [PubMed: 22403656]  [MGI Ref ID J:186852]

Poorthuis BJ; Romme AE; Willemsen R; Wagemaker G. 1994. Bone marrow transplantation has a significant effect on enzyme levels and storage of glycosaminoglycans in tissues and in isolated hepatocytes of mucopolysaccharidosis type VII mice. Pediatr Res 36(2):187-93. [PubMed: 7970933]  [MGI Ref ID J:22149]

Sands MS; Birkenmeier EH. 1993. A single-base-pair deletion in the beta-glucuronidase gene accounts for the phenotype of murine mucopolysaccharidosis type VII. Proc Natl Acad Sci U S A 90(14):6567-71. [PubMed: 8101990]  [MGI Ref ID J:13207]

Sands MS; Vogler C; Kyle JW; Grubb JH; Levy B; Galvin N; Sly WS; Birkenmeier EH. 1994. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 93(6):2324-31. [PubMed: 8200966]  [MGI Ref ID J:19122]

Sferra TJ; Qu G; McNeely D; Rennard R; Clark KR; Lo WD; Johnson PR. 2000. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse Hum Gene Ther 11(4):507-19. [PubMed: 10724030]  [MGI Ref ID J:61251]

Simonaro CM; Ge Y; Eliyahu E; He X; Jepsen KJ; Schuchman EH. 2010. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A 107(1):222-7. [PubMed: 20018674]  [MGI Ref ID J:156466]

Skorupa AF; Fisher KJ; Wilson JM; Parente MK; Wolfe JH. 1999. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 160(1):17-27. [PubMed: 10630187]  [MGI Ref ID J:58536]

Sly WS; Vogler C; Grubb JH; Zhou M; Jiang J; Zhou XY; Tomatsu S; Bi Y; Snella EM. 2001. Active site mutant transgene confers tolerance to human beta -glucuronidase without affecting the phenotype of MPS VII mice. Proc Natl Acad Sci U S A 98(5):2205-10. [PubMed: 11226217]  [MGI Ref ID J:67876]

Snyder EY; Taylor RM; Wolfe JH. 1995. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 374(6520):367-70. [PubMed: 7885477]  [MGI Ref ID J:23926]

Soper BW; Duffy TM; Vogler CA; Barker JE. 1999. A genetically myeloablated MPS VII model detects the expansion and curative properties of as few as 100 enriched murine stem cells. Exp Hematol 27(11):1691-704. [PubMed: 10560917]  [MGI Ref ID J:58272]

Stein CS; Ghodsi A; Derksen T; Davidson BL. 1999. Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 73(4):3424-9. [PubMed: 10074197]  [MGI Ref ID J:53465]

Tomatsu S; Orii KO; Vogler C; Nakayama J; Levy B; Grubb JH; Gutierrez MA; Shim S; Yamaguchi S; Nishioka T; Montano AM; Noguchi A; Orii T; Kondo N; Sly WS. 2003. Mouse model of N-acetylgalactosamine-6-sulfate sulfatase deficiency (Galns-/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum Mol Genet 12(24):3349-58. [PubMed: 14583446]  [MGI Ref ID J:87155]

Vogler C; Sands M; Higgins A; Levy B; Grubb J; Birkenmeier EH; Sly WS. 1993. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res 34(6):837-40. [PubMed: 8108204]  [MGI Ref ID J:22453]

Wolfe JH; Deshmane SL; Fraser NW. 1992. Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nat Genet 1(5):379-84. [PubMed: 1338772]  [MGI Ref ID J:1832]

Woloszynek JC; Coleman T; Semenkovich CF; Sands MS. 2007. Lysosomal dysfunction results in altered energy balance. J Biol Chem 282(49):35765-71. [PubMed: 17911106]  [MGI Ref ID J:129210]

Woloszynek JC; Roberts M; Coleman T; Vogler C; Sly W; Semenkovich CF; Sands MS. 2004. Numerous transcriptional alterations in liver persist after short-term enzyme-replacement therapy in a murine model of mucopolysaccharidosis type VII. Biochem J 379(Pt 2):461-9. [PubMed: 14705966]  [MGI Ref ID J:88886]

Health & husbandry

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Health & Colony Maintenance Information

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200.

Colony Maintenance

Breeding & Husbandry	When maintaining a live colony, heterozygous mice are bred together. Mice homozygous for this recessive mutation are viable, but exhibit breeding problems.

Pricing and Purchasing

Pricing, Supply Level & Notes, Controls

General Supply Notes

• View the complete collection of spontaneous mutants in the Mouse Mutant Resource.

Control Information

	Control
	Wild-type from the colony
	000664 C57BL/6J
Considerations for Choosing Controls
Control Pricing Information for Genetically Engineered Mutant Strains.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

See Terms of Use tab for General Terms and Conditions

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering Information
JAX^® Mice
Surgical and Preconditioning Services
JAX^® Services
Customer Services and Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries regarding Terms of Use

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCTS" means biological materials supplied by JACKSON, and their derivatives. "RECIPIENT" means each recipient of MICE, PRODUCTS, or services provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than the internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE or PRODUCTS from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON's prior written authorization.

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.